^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Resimmune (VG712)

    i
    Other names: VG712, A-dmDT390-bisFv(UCHT1), UCHT-1, A-dmDT390-anti-CD3 immunotoxin, A-dmDT390-bisFv, LAX-699, LAX699, UCHT1, VG-712, LAX 699, UCHT 1, VG 712
    Associations

    News

    Trials
    Company:
    AOP Orphan Pharma, Angimmune, Virogen Biotech
    Drug class:
    Elongation factor 2 inhibitor, CD3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    23d
    Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides (clinicaltrials.gov)
    P2, N=0, Withdrawn, Virogen Biotechnology Inc. | N=162 --> 0 | Trial completion date: May 2020 --> May 2026 | Unknown status --> Withdrawn | Trial primary completion date: Dec 2018 --> May 2026
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    Zolinza (vorinostat) • Resimmune (VG712)
    2ms
    CurbMF: A Study of VG712 in Patients With Mycosis Fungoides (clinicaltrials.gov)
    P2, N=386, Not yet recruiting, Virogen Biotechnology Inc.
    New P2 trial
    |
    Poteligeo (mogamulizumab-kpkc) • Resimmune (VG712)